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another agenda, but it was at the end of the day and my
superbly tuned incisive diagnostic skills were not at their
sharpest. We ended on that note and as he got to the door he
said, as an aside, ‘I believe there is a pill for it nowadays’.  I
knew intuitively exactly what he was talking about. He was
referring to Viagra and we went on to raise the subject, so to
speak.
My most recent door-handle symptom involved a man with
sores on his arms and legs.  I explained that they were Natal or
veld sores and were caused by bacteria.  I prescribed antibiotics
to take by mouth and a nasal cream, which I explained was to
kill the reservoir of organisms in his nose.  As he went out of
the door he hesitated and said ‘do you think I should have an
AIDS test?’. I asked why he thought this was necessary. He
replied that a worker in his factory had just died of AIDS and
his symptoms had started with skin sores.  I had treated his
condition, but I had completely missed his reason for coming
to see me.
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The National Adverse Event Monitoring Centre (NADEMC)
of the Medicines Control Council wishes to draw the
attention of health practitioners to the fact that Naropin
(ropivacaine) is not approved for use in children under 1
year of age, as safety and efficacy in this population have
not been established.
For paediatric use ropivacaine is approved for acute
pain management using caudal epidural or peripheral
nerve block in the pre- and postoperative setting.1 Safety
and efficacy have not been established in children under the
age of 1 year.  The package insert gives no dose for children
under 1 year of age.
The NADEMC has a total of 21 adverse reaction reports
with 47 adverse reaction terms in its database where
ropivacaine is indicated as the medicine suspected to have
caused the event. Three of these reports followed the use of
ropivacaine in infants less than 1 year of age:
• A 2-month-old male infant (2.1 kg) was given a caudal
block with ropivacaine, and 13 minutes later developed
apnoea, bradycardia and pallor. He responded to
treatment with oxygen and atropine. He required no
further treatment apart from tactile stimulation and
aminophylline. This infant had been born at 28 weeks’
gestation and had a history of apnoeic spells.
• A 2-month-old male infant (2.5 kg) experienced apnoea
followed by bradycardia and cyanosis 5 minutes after
ropivacaine administration for caudal block. He
recovered on treatment. The infant had been born
prematurely, but had no history of apnoea.
• A 6-month-old infant (7.8 kg), treated with ropivacaine
for postoperative analgesia by epidural infusion over 2
days, was noted to be jittery with continuous abnormal
movements of the upper limb, which were more
pronounced when he was awake. The symptoms slowly
resolved after the infusion was stopped. Analysis of
blood samples showed ropivacaine levels below those
expected to result in systemic toxicity based on findings
in adults.
In all three cases the events were assessed as possibly
having been causally associated with Naropin because of
the temporal relationship to its administration. The role of
other causes, including the clinical status of the infants,
could not be excluded.
The systemic toxicity of local anaesthetics, including
ropivacaine, mainly involves the central nervous system
(CNS) and the cardiovascular system. Excitation of the CNS
may be manifested by restlessness, excitement, nervousness,
paraesthesiae, dizziness, tinnitus, blurred vision, nausea
and vomiting, muscle twitching and tremors, and
convulsions. Excitation may be transient and followed by
depression with drowsiness, respiratory failure and coma.
Cardiovascular system effects of local anaesthetics include
myocardial depression and peripheral vasodilatation
resulting in hypotension and bradycardia, arrhythmias and
cardiac arrest.
Health care professionals are requested to report any
suspected reactions associated with the use of Naropin or
any other medicines to the National Adverse Drug Event
Monitoring Centre at (021) 447-1618, fax (021) 448-6181.
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